► Customized research for MLNT vs. DYAI!
► All in one page research, scroll down. Compare two other stocks.
► Note: Don't forget to explore SpeculatingStocks further... from the SpeculatingStocks.com Homepage you can Discover Stocks, Post Anonymously, and React. No Login Required.
Done! Side by Side Research Below for MLNT vs. DYAI.
↗ Join Our Free Email Newsletter.
► Melinta Therapeutics Inc. vs. Dyadic International, Inc.
Industry Match! Industry of Both MLNT and DYAI:
Health Care/Life Sciences
MLNT
Data Last Updated: 2 days ago
↻ Update Column 1 to Most Recent
► Key Statistics
Cap: 22M
P/E: N/A
P/S: 0.23
Q P/B: N/A
Y Rev: 96.43M
Q Rev: 15.87M
Beta: 6.80

MLNT Share Stats
► Outstanding Shares
11.78M
► Float Shares
10.37M
► Percent of Float Short
20.47%
MLNT Insider Stats
► Percent Outstanding Insider Ownership
8.55%
► Percent Outstanding Institution Ownership
27.56%
MLNT Social Stats
► Followers
0
► B/S Rating Today
0
► B/S Rating All-Time
N/A
Share MLNT Insights
MLNT Profile
► CEO
Ms. Jennifer A. Sanfilippo
► Exchange
Nasdaq
► Employees
290.00
► About
Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv,...

MLNT Financials
Annual Financials
Income Statement
► Revenue
96.43M
► Net Income
(157.19M)
Cash Flow Statement
► Change in Cash / Investments
(46.58M)
Balance Sheet
► Cash / Investments
81.81M
► Short Term Debt
None
► Long Term Debt
110.48M
► Total Current Assets
149.48M
► Total Current Liabilities
133.61M
► Total Assets
441.59M
► Total Liabilities
251.53M
► Stockholder Equity
190.06M
Quarterly Financials
Income Statement
► Q Revenue
15.87M
► Q Net Income
(213.38M)
Cash Flow Statement
► Q Change in Cash / Investments
(26.82M)
Balance Sheet
► Q Cash / Investments
63.52M
► Q Short Term Debt
7.82M
► Q Long Term Debt
152.79M
► Q Total Current Assets
131.27M
► Q Total Current Liabilities
128.05M
► Q Total Assets
228.49M
► Q Total Liabilities
289.02M
► Q Stockholder Equity
(60.53M)

MLNT Charts
► 10-Year Chart

► 5-Year Chart

► 1-Year Chart

► 6-Month Chart

► 3-Month Chart

► 1-Month Chart

► 1-Day Chart

DYAI
Data Last Updated: More than a wk ago
↻ Update Column 2 to Most Recent
► Key Statistics
Cap: 163.551M
P/E: N/A
P/S: 125.81
Q P/B: 4.39
Y Rev: 1.3M
Q Rev: 454,507
Beta: 0.20

DYAI Share Stats
► Outstanding Shares
26.76M
► Float Shares
18.92M
► Percent of Float Short
4.23%
DYAI Insider Stats
► Percent Outstanding Insider Ownership
0%
► Percent Outstanding Institution Ownership
15.44%
DYAI Social Stats
► Followers
0
► B/S Rating Today
0
► B/S Rating All-Time
N/A
Share DYAI Insights
DYAI Profile
► CEO
Mr. Mark A. Emalfarb
► Exchange
Nasdaq
► Employees
8.00
► About
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development,...

DYAI Financials
Annual Financials
Income Statement
► Revenue
1.3M
► Net Income
(5.69M)
Cash Flow Statement
► Change in Cash / Investments
(3.4M)
Balance Sheet
► Cash / Investments
41.2M
► Short Term Debt
None
► Long Term Debt
None
► Total Current Assets
42.75M
► Total Current Liabilities
849,638
► Total Assets
43.3M
► Total Liabilities
849,638
► Stockholder Equity
42.45M
Quarterly Financials
Income Statement
► Q Revenue
454,507
► Q Net Income
(1.7M)
Cash Flow Statement
► Q Change in Cash / Investments
(119,193)
Balance Sheet
► Q Cash / Investments
35.46M
► Q Short Term Debt
None
► Q Long Term Debt
None
► Q Total Current Assets
36.46M
► Q Total Current Liabilities
1.28M
► Q Total Assets
38.52M
► Q Total Liabilities
1.28M
► Q Stockholder Equity
37.24M

DYAI Charts
► 10-Year Chart

► 5-Year Chart

► 1-Year Chart

► 6-Month Chart

► 3-Month Chart

► 1-Month Chart

► 1-Day Chart

